Journal of Breast Cancer

Korean Breast Cancer Society (한국유방암학회)
권호 표지
DOI QR코드

DOI QR Code

Internal Mammary Sentinel Lymph Node Biopsy after Neoadjuvant Chemotherapy in Breast Cancer

  • Bi, Zhao (School of Medicine and Life Sciences, University of Jinan-Shandong Academy of Medical Sciences) ;
  • Chen, Peng (Breast Cancer Center, Shandong Cancer Hospital Affiliated to Shandong University) ;
  • Liu, Jingjing (Department of Blood Transfusion, The Affiliated Hospital of Qingdao University) ;
  • Liu, Yanbing (Breast Cancer Center, Shandong Cancer Hospital Affiliated to Shandong University) ;
  • Qiu, Pengfei (Breast Cancer Center, Shandong Cancer Hospital Affiliated to Shandong University) ;
  • Yang, Qifeng (Department of Breast Surgery, Qilu Hospital, Shandong University) ;
  • Zheng, Weizhen (School of Medicine and Life Sciences, University of Jinan-Shandong Academy of Medical Sciences) ;
  • Wang, Yongsheng (Breast Cancer Center, Shandong Cancer Hospital Affiliated to Shandong University)
  • Received : 2018.02.08
  • Accepted : 2018.09.10
  • Published : 2018.12.31
⟨ Previous Next ⟩

Abstract

Purpose: The definition of nodal pathologic complete response (pCR) after a neoadjuvant chemotherapy (NAC) just included the evaluation of axillary lymph node (ALN) without internal mammary lymph node. This study aimed to evaluate the feasibility of internal mammary-sentinel lymph node biopsy (IM-SLNB) in patients with breast cancer who underwent NAC. Methods: From November 2011 to 2017, 179 patients with primary breast cancer who underwent operation after NAC were included in this study. All patients received radiotracer injection with modified injection technology. IM-SLNB would be performed on patients with internal mammary sentinel lymph node (IMSLN) visualization. Results: Among the 158 patients with cN+ disease, the rate of nodal pCR was 36.1% (57/158). Among the 179 patients, the visualization rate of IMSLN was 31.8% (57/179) and was 12.3% (7/57) and 87.7% (50/57) among those with $cN_0$ and cN+ disease, respectively. Furthermore, the detection rate of IMSLN was 31.3% (56/179). The success rate of IM-SLNB was 98.2% (56/57). The IMSLN metastasis rate was 7.1% (4/56), and all of them were accompanied by ALN metastasis. The number of positive ALNs in patients with IMSLN metastasis was 3, 6, 8, and 9. The pathology nodal stage had been changed from $pN_1/pN_2$ to $pN_{3b}$. The pathology stage had been changed from IIA/IIIA to IIIC. Conclusion: Patients with visualization of IMSLN should perform IM-SLNB after NAC, especially for patients with cN+ disease, in order to complete lymph nodal staging. IM-SLNB could further improve the definition of nodal pCR and guide the internal mammary node irradiation.

Keywords

Acknowledgement

Supported by : National Natural Science Foundation of China

References

  1. Fisher B, Brown A, Mamounas E, Wieand S, Robidoux A, Margolese RG, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 1997;15:2483-93. https://doi.org/10.1200/JCO.1997.15.7.2483
  2. Li XB, Krishnamurti U, Bhattarai S, Klimov S, Reid MD, O'Regan R, et al. Biomarkers predicting pathologic complete response to neoadjuvant chemotherapy in breast cancer. Am J Clin Pathol 2016;145:871-8. https://doi.org/10.1093/ajcp/aqw045
  3. Caudle AS, Yi M, Hoffman KE, Mittendorf EA, Babiera GV, Hwang RF, et al. Impact of identification of internal mammary sentinel lymph node metastasis in breast cancer patients. Ann Surg Oncol 2014;21:60-5. https://doi.org/10.1245/s10434-013-3276-z
  4. Kumar A, Puri R, Gadgil PV, Jatoi I. Sentinel lymph node biopsy in primary breast cancer: window to management of the axilla. World J Surg 2012;36:1453-9. https://doi.org/10.1007/s00268-012-1635-8
  5. Cong BB, Qiu PF, Wang YS. Internal mammary sentinel lymph node biopsy: minimally invasive staging and tailored internal mammary radiotherapy. Ann Surg Oncol 2014;21:2119-21. https://doi.org/10.1245/s10434-014-3650-5
  6. Qiu PF, Cong BB, Zhao RR, Yang GR, Liu YB, Chen P, et al. Internal mammary sentinel lymph node biopsy with modified injection technique: high visualization rate and accurate staging. Medicine (Baltimore) 2015;94:e1790. https://doi.org/10.1097/MD.0000000000001790
  7. Irigo M, Coscarelli L, Rancati A. Anatomical basis of pedicles in breast reduction. Gland Surg 2017;6:154-62. https://doi.org/10.21037/gs.2016.09.11
  8. Suami H, Pan WR, Mann GB, Taylor GI. The lymphatic anatomy of the breast and its implications for sentinel lymph node biopsy: a human cadaver study. Ann Surg Oncol 2008;15:863-71. https://doi.org/10.1245/s10434-007-9709-9
  9. Li D, Chen JH, Yao Q, Yang H, Wang L. Determination of lymphatic vessel density in breast cancer patients receiving neoadjuvant chemotherapy. China Oncol 2007;17:754-7.
  10. Kuerer HM, Hunt KK. The rationale for integration of lymphatic mapping and sentinel node biopsy in the management of breast cancer after neoadjuvant chemotherapy. Semin Breast Dis 2002;5:80-7.
  11. Sharkey FE, Addington SL, Fowler LJ, Page CP, Cruz AB. Effects of preoperative chemotherapy on the morphology of resectable breast carcinoma. Mod Pathol 1996;9:893-900.
  12. Tsuyuki S, Yamaguchi A, Kawata Y, Kawaguchi K. Assessing the effects of neoadjuvant chemotherapy on lymphatic pathways to sentinel lymph nodes in cases of breast cancer: usefulness of the indocyanine green-fluorescence method. Breast 2015;24:298-301. https://doi.org/10.1016/j.breast.2015.02.034
  13. van der Ent FW, Kengen RA, van der Pol HA, Povel JA, Stroeken HJ, Hoofwijk AG. Halsted revisited: internal mammary sentinel lymph node biopsy in breast cancer. Ann Surg 2001;234:79-84. https://doi.org/10.1097/00000658-200107000-00012
  14. Cao XS, Li HJ, Cong BB, Sun X, Qiu PF, Liu YB, et al. Axillary and internal mammary sentinel lymph node biopsy in breast cancer after neoadjuvant chemotherapy. Oncotarget 2016;7:74074-81.
  15. Budach W, Kammers K, Boelke E, Matuschek C. Adjuvant radiotherapy of regional lymph nodes in breast cancer: a meta-analysis of randomized trials. Radiat Oncol 2013;8:267. https://doi.org/10.1186/1748-717X-8-267
  16. Breast cancer, version 3.2017 featured updates to the NCCN guidelines. National Comprehensive Cancer Network. http://www.nccn.org. Accessed November 10th, 2017.
  17. Huang O, Wang L, Shen K, Lin H, Hu Z, Liu G, et al. Breast cancer subpopulation with high risk of internal mammary lymph nodes metastasis: analysis of 2,269 Chinese breast cancer patients treated with extended radical mastectomy. Breast Cancer Res Treat 2008;107:379-87. https://doi.org/10.1007/s10549-007-9561-4
  18. Bi Z, Qiu PF. Advances in diagnosis and treatment of internal mammary lymph node of breast cancer. Chin J Clin Oncol 2017;44:1104-7.
  19. Qiu PF, Liu YB, Wang YS. Internal mammary sentinel lymph node biopsy: abandon or persist? Onco Targets Ther 2016;9:3879-82. https://doi.org/10.2147/OTT.S106519

Cited by

  1. Definition of Internal Mammary Node Target Volume Based on the Position of the Internal Mammary Sentinel Lymph Nodes Presented on SPECT/CT Fusion Images vol.9, pp.None, 2020, https://doi.org/10.3389/fonc.2019.01553